At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials ...

After nearly two decades of research, India’s first dengue vaccine, DengiAll, is ready to make its mark. Designed to fight ...

The shares of Panacea Biotec touched its 52-week high of ₹581 on May 15, 2025, and a 52-week low of ₹282.15 on February 28, ...

Karnataka reports zero dengue deaths for the first time in five years with a significant 82% drop in cases, attributed to ...

For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous ...

Dengue is known as the “break-bone fever” for a reason. A disease that includes symptoms like piercing headaches, fever and joint pain, is now threatening nearly half the world’s population. The World ...

The annual number of dengue fever cases in India is 282 times higher than officially reported, and the disease inflicts an economic burden on the country of at least US$1.11 billion each year in ...

NEW DELHI: Dengue is a dangerous debilitating disease that occasionally kills people and has no known cure or treatment. Two vaccines against the dreaded disease - one foreign and one Indian - await ...

The annual number of dengue fever cases in India is 282 times higher than officially reported, and the disease inflicts an economic burden on the country of at least US$1.11 billion each year in ...

Deerfield, Ill. (October 8, 2014) — The annual number of dengue fever cases in India is 282 times higher than officially reported, and the disease inflicts an economic burden on the country of at ...